Media

November 6, 2026 | Presentations
Direct intratumoral delivery of Amphiphilic ImmunoModulators (AIM) induces durable anti-tumor efficacy
November 6, 2026 | Presentations
Seven valent mKRAS lymph node targeted amphiphile vaccine drives mKRAS-specific T cell responses that correlate with improved clinical outcomes in the AMPLIFY-7P randomized phase 2 trial
October 24, 2026 | Video
Camupepimut shows early disease free survival signal in resected KRAS mutated pancreatic cancer – video
October 23, 2026 | Publication
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial
May 29, 2026 | Publication
Lymph node–targeted DNA engages TBK1/IFN-I–Driven innate immunity to induce potent T cell responses and durable memory in mice and NHPs
November 7, 2025 | Publication
AMP-ImmunoModulator (AIM) Therapy Controls Growth and Eradicates Syngeneic Solid Tumors
November 7, 2025 | Publication
AMPLIFY-7P Phase 2: T cell responses induced by lymph node-targeted amphiphile therapeutic cancer vaccine in patients with KRAS mutated pancreatic ductal adenocarcinoma
September 17, 2025 | Publication
AMPLIFY-7P Phase 2 Immunogenicity Data
November 7, 2024 | Publication
AMPLIFY-7P Phase 1a: Lymph node-targeted amphiphile therapeutic cancer vaccine in patients with high relapse risk KRAS mutated pancreatic ductal adenocarcinoma and colorectal cancer
June 1, 2024 | Publication
AMPLIFY-7P, a first in human safety and efficacy trial of adjuvant mKRAS-specific lymph node-targeted Amphiphile ELI-002 7P vaccine in minimal residual disease positive pancreatic and colorectal cancer patients (ASCO 2024 – Scientific Poster)